Photo Credit: AI
The following is a summary of “Effective and durable repigmentation for stable vitiligo: A randomized within-subject controlled trial assessing treatment with autologous skin cell suspension transplantation,” published in the December 2024 issue of Dermatology by Hamzavi et al.
Vitiligo lesions were challenging to repigment with conventional therapies, and while surgical autologous melanocyte transfer was used for stable cases, it required specialized skills and equipment, leading to the development of a point-of-care autologous cell harvesting device for easy preparation of autologous skin cell suspension (ASCS) containing melanocytes, keratinocytes, and fibroblasts for cellular transplantation.
Researchers conducted a retrospective study to assess the safety and effectiveness of ASCS in adults for the repigmentation of stable vitiligo lesions.
They compared ASCS to narrow band ultraviolet B treatment (Control) on similar vitiligo lesions in a multicenter, randomized, within-subject controlled trial. The ASCS was applied after laser skin resurfacing, followed by narrow band ultraviolet B treatment. The primary effectiveness endpoint was the proportion of lesions achieving ≥80% repigmentation at week 24, with repigmentation durability assessed at week 52.
The results showed among 25 subjects, 36% of ASCS-treated lesions achieved ≥80% repigmentation at week 24, compared to 0% in the Control group (P < .025), with repigmentation durability maintained through week 52. The safety profile of ASCS was acceptable, with positive outcomes reported by both patients and investigators.
Investigators concluded the application of ASCS demonstrated potential as a promising treatment for repigmentation of stable vitiligo lesions, with the potential to improve health-related QoL and reduce the disease burden.
Source: sciencedirect.com/science/article/pii/S0190962224027130
